Arcutis (ARQT) Q4 2025: Zareve Captures 45% Segment Share as Non-Steroidal Topicals Displace Steroids

2026-02-25 | By EarningsIQ Research

Zareve’s commercial momentum and label expansion powered Arcutis to a pivotal year of market share gains and operational leverage. The company’s disciplined access and pricing strategy insulated margins while broadening payer coverage, enabling a guidance raise and sustained cash flow positivity into 2026. Investors should focus on the accelerating shift away from topical steroids and the untapped potential in pediatric and primary care channels as Arcutis deepens its franchise.

Summary

• Market Share Shift: Zareve’s 45% branded non-steroidal topical share signals a durable channel migration away from steroids.
• Operational Leverage: Cash flow inflection and disciplined SG&A investment support pipeline and sales force expansion.
• Guidance Confidence: Raised 2026 outlook reflects durable demand, expanded indications, and payer access tailwinds.

Performance Analysis

Arcutis delivered a breakout fourth quarter, with Zareve, its non-steroidal topical franchise, driving robust double-digit sequential and year-over-year revenue growth. The company’s net product revenues were propelled by a doubling of prescription volume, reflecting strong adoption across psoriasis, seborrheic dermatitis, and atopic dermatitis. Zareve’s profile as a safe, advanced topical alternative to steroids continues to resonate with both clinicians and patients, underpinning its ascent as the leading branded non-steroidal topical in the segment.

Operational leverage emerged as a clear theme, with cost discipline and scale from Zareve’s growth resulting in a shift to positive cash flow and net income. SG&A increases were targeted, funding both a 20% dermatology sales force expansion and the new pilot primary care/pediatric team. Gross-to-net ratios remained stable in the 50s, a marked contrast to peers facing margin erosion, and management expects this resilience to persist in 2026. The company’s capital position is further strengthened by $221 million in cash and marketable securities and the option to draw additional debt if needed.

• Prescription Volume Expansion: Zareve’s prescription base doubled year-over-year, cementing leadership in non-steroidal topicals.
• Stable Gross-to-Net: No material margin erosion, despite expanded access and payer wins.
• Cash Flow Inflection: Positive cash generation supports continued investment in pipeline and commercial buildout.

Looking ahead, Arcutis expects typical Q1 seasonality but projects sequential growth resuming from Q2, with new sales force investments expected to drive further share gains in the back half of 2026.

Executive Commentary

Strategic Positioning

1. Zareve Franchise Expansion

Arcutis’s core strategy centers on maximizing Zareve’s reach by expanding approved indications and formulations. The recent FDA approvals for Zareve foam (scalp/body psoriasis) and cream (atopic dermatitis ages two to five) have opened incremental patient pools, while a supplemental NDA for pediatric psoriasis and positive Phase 2 data in infants with atopic dermatitis signal further label expansion opportunities in 2026.

2. Access and Payer Strategy

The company’s differentiated pricing and access approach has enabled Zareve to achieve over 80% commercial coverage and significant Medicare and Medicaid wins, without sacrificing gross-to-net economics. Zareve is now the only branded non-steroidal topical on several Medicare Part D formularies, a rare feat in a generics-favored channel, though it remains on the non-preferred tier with higher copays.

3. Sales Force and Channel Diversification

Arcutis is scaling its commercial presence with a 20% increase in dermatology reps and the launch of an internal primary care/pediatric sales pilot. This stepwise approach targets high-volume prescribers and leverages dermatologist advocacy, aiming to capture share as the migration from topical steroids accelerates in broader care settings. Management expects these investments to be accretive in the second half of 2026.

4. Pipeline and Lifecycle Management

Beyond Zareve, Arcutis is advancing ARQ234, a novel biologic targeting CD200R for atopic dermatitis, with a Phase 1 trial commencing soon. Ongoing Phase 2 proof-of-concept studies in vitiligo and hidradenitis suppurativa represent pipeline-in-a-molecule opportunities, with data readouts expected in late 2026 and early 2027, respectively.

5. Operating Leverage and Capital Allocation

Disciplined capital deployment is prioritized, with reinvestment focused on high-ROI commercial and development opportunities. Management is clear that adding commercial-stage assets is a low priority, preferring to maximize Zareve’s margin and pipeline value.

Key Considerations

Arcutis’s 2025 performance underscores a business model built on clinical differentiation, payer strategy, and operational discipline. Investors should weigh the following:

• Share Displacement Dynamics: Each 1% share shift from topical corticosteroids translates to roughly 15% volume growth for branded non-steroidal topicals, with Zareve capturing the majority of this migration.
• Pediatric and Primary Care Penetration: Recent and pending label expansions, combined with targeted sales force pilots, position Arcutis to unlock new patient segments and drive durable growth.
• Gross-to-Net Resilience: Pricing and access discipline have insulated margins, with no anticipated rebate-driven erosion despite broader access wins.
• Pipeline Optionality: Multiple near-term clinical catalysts in pediatric indications and new disease areas provide upside optionality for the Zareve franchise and the broader pipeline.

Risks

Key risks include: potential regulatory delays on supplemental NDAs, slower-than-expected uptake in primary care or Medicare due to non-preferred formulary status, and competitive pressure from new branded or generic entrants. While the gross-to-net has proven stable, any shifts in payer mix or rebate dynamics could impact profitability. Macroeconomic or legislative changes to PBM or reimbursement structures remain a sector-wide overhang, though management expresses confidence in their positioning regardless of policy shifts.

Forward Outlook

For Q1 2026, Arcutis expects:

• Seasonal reduction in net product revenue due to deductible resets and higher copay usage
• Gross-to-net in the high 50s, improving throughout the year

For full-year 2026, management raised net product revenue guidance to:

• $480 million to $495 million (up from prior $455 million to $470 million)

Management emphasized:

• Sequential growth will resume post-Q1, supported by expanding sales force and new patient access
• Positive cash flow will be maintained each quarter, even as investment increases

Takeaways

Arcutis’s Q4 and full-year results affirm the durability and scalability of the Zareve franchise as the branded non-steroidal topical segment accelerates its share gains from steroids. The company’s ability to combine payer access, clinical innovation, and cost discipline sets it apart in a competitive landscape.

• Share Gains Drive Leverage: Zareve’s 45% segment share and doubled prescription volume are translating into operating leverage and cash flow inflection, supporting further commercial and pipeline investment.
• Strategic Access Pays Off: A deliberate pricing and access model has preserved margins while broadening coverage, with Medicare and Medicaid wins validating the strategy.
• Pipeline and Channel Expansion Key for 2026: Investors should monitor the impact of pediatric label expansions, primary care pilot ramp, and progress in new indications as determinants of sustained outperformance.

Conclusion

Arcutis enters 2026 with strong momentum, a fortified Zareve franchise, and a clear roadmap for continued growth. The company’s execution on access, operational scale, and pipeline advancement supports its raised guidance and positions it as a leader in the evolving dermatology market. Sustained share gains and disciplined investment remain the key levers for value creation.

Industry Read-Through

Arcutis’s performance highlights a decisive shift in dermatology prescribing patterns, with branded non-steroidal topicals rapidly gaining share from legacy steroids. The stability in gross-to-net, despite payer expansion, demonstrates the value of a disciplined access and pricing strategy in specialty pharma. Competitors in dermatology and adjacent chronic inflammatory categories should note the accelerating demand for safer, targeted therapies and the importance of payer strategy in unlocking both commercial and Medicare channels. The sector-wide migration away from steroids is likely to continue, rewarding those with differentiated clinical profiles and robust access infrastructure.

ARQT Healthcare Pharmaceuticals Dermatology Prescription Drugs Payer Access Pipeline Operational Leverage